

Market Data

Annovis Bio
NYSE AMERICAN: ANVS

Fiscal Year End: December 31

Industry: Biotechnology

Recent Price¹: \$50.77

Market Cap¹: \$396M

Shares Out.: 7.8M

Float: 5.3M

Avg. Volume¹ (90-day): 1.0M

¹ as of May 25, 2021


annovisbio.com

Corporate Headquarters
1055 Westlakes Drive
Suite 300
Berwyn, PA 19312

Company Overview

Annovis Bio is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. Annovis has an ongoing Phase 2a study in AD patients and a second Phase 2a study in early PD and early AD patients. Initial data, reported in the first half of 2021, showed ANVS401, the company’s lead candidate, improved speed and coordination scores and lowered levels of key inflammatory markers in PD patients and improved cognition in AD patients.

Pipeline



Value Proposition

Annovis is developing novel solutions for the treatment of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD), multibillion dollar markets with significant unmet needs.

The company’s Phase 2a clinical trial in AD is taking place at six sites, including the University of California, San Diego, Johns Hopkins, Indiana University, Washington University, the Cleveland Clinic, and Columbia University. This trial is a 24-patient study, with 14 patients who have been enrolled with no adverse effects reported to date. There have been 500+ failed attempts at developing AD drugs, primarily targeting sticky brain plaques. Annovis has taken a different/novel approach, focusing on improving axonal transport, the information highway of the nerve cell, by attacking multiple neurotoxic proteins simultaneously.


The Company began recruiting in August 2020 for a second Phase 2a study in early PD and early AD patients at 15 sites with primary endpoints targeting a decrease in neurotoxic protein levels, increase in neurotransmitters and neurotrophic factors, lowering of inflammatory proteins and lowering of neurodegeneration markers. Positive interim data was reported in the first half of 2021, showing ANVS401 improved speed and coordination scores and lowered levels of key inflammatory markers in PD patients and improved cognition in AD patients. The positive data spurred institutional investors to invest \$50 million in a follow-on offering priced at \$50 per share.

The costs of care for Americans with Alzheimer’s and other dementias was estimated at \$277 billion in 2018 and is expected to surpass \$1.1 trillion by 2050.

RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time. The information contained herein is not intended to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not a representation or warranty and is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., our specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or timeliness of the information provided, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information provided to any person or entity (including but not limited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information). Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print. We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov. Annovis (ANVS) is a client of RedChip Companies, Inc. ANVS agreed to pay RedChip Companies, Inc. a \$8,500 monthly cash fee, beginning in February 2020, for RedChip investor awareness services and consulting services. Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.

Patent Portfolio

Multi-layer strategy



Patent/Application	Subject Matter	Status US	Expiry US
PCT	ANVS401 and 405 - Method of use of MOA for prevention and treatment of diseases	Pending	2038
PCT	ANVS405 - Acute brain and nerve injuries	Pending	2036
PCT	ANVS401 - pK/pD, low doses, formulations Neurodegenerative Diseases	US 10,383,851 Issued August 2019	2031
In-licensed patents	Composition of matter, manufacturing, method for treating AD and DS	Granted	2022-25

Investment Highlights

- Novel solution to stop the course of Alzheimer’s (AD) and Parkinson’s (PD) underpinned by 19 animal studies; 3 Phase 1 human studies and multiple clinical trials underway
- One ongoing Phase 2a trial in AD and one Phase 2a study in early PD and early AD patients; interim data reported in first half of 2021 demonstrated:
 - Patients’ speed and coordination scores both improved and levels of key inflammatory marker were significantly lowered in Parkinson’s arm of study
 - ANVS401 improves cognition in Alzheimer’s disease – patients’ cognition improved 3.3 points on ADAS-Cog11
- Positive interim data fueled strong institutional interest in May 2021 follow-on offering; Company raised \$50M at \$50 per share
- Capital raise expected to fund planned Phase 3 trial in AD in persons with Down Syndrome
- Markets for AD and PD drugs are in the multibillions of dollars and growing
- Only company known to improve axonal transport by inhibiting the translation of multiple neurotoxic proteins
- Multi-layered patent protection strategy covering our drugs through 2038
- Highly experienced management team complemented by strong board of directors and world-renowned scientific advisory board
- Analyst coverage and buy ratings from Maxim Group and ThinkEquity